0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Activatable Semiconducting Polymer Pro‐nanomodulators for Deep‐Tissue Sono‐immunotherapy of Orthotopic Pancreatic Cancer

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          The blockade of immune checkpoints in cancer immunotherapy.

          Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer immunotherapy comes of age.

            Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Cancer nanomedicine for combination cancer immunotherapy

                Bookmark

                Author and article information

                Contributors
                Journal
                Angewandte Chemie
                Angewandte Chemie
                Wiley
                0044-8249
                1521-3757
                June 06 2023
                Affiliations
                [1 ] State Key Laboratory for Modification of Chemical Fibers and Polymer Materials College of Biological Science and Medical Engineering Donghua University Shanghai 201620 China
                [2 ] School of Chemistry Chemical Engineering and Biotechnology Lee Kong Chian School of Medicine Nanyang Technological University 70 Nanyang Drive Singapore 637457 Singapore
                [3 ] School of Chemistry and Chemical Engineering Shanghai Engineering Technology Research Center for Pharmaceutical Intelligent Equipment Shanghai University of Engineering Science Shanghai 201620 China
                Article
                10.1002/ange.202305200
                97862d24-dbfb-4919-ae91-bf535a8ae73f
                © 2023

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                History

                Comments

                Comment on this article